Rislenemdaz
id:
rislenemdaz-184-18003977
title:
Rislenemdaz
text:
Rislenemdaz is an orally active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, rislenemdaz received Fast Track Designation from the Food and Drug Administration for TRD. A pilot study was published in 2012, and a phase II trial was completed in 2014, but was deemed insufficient. A sec
brand slug:
wiki
category slug:
encyclopedia
description:
Investigational antidepressant compound
original url:
https://en.wikipedia.org/wiki/Rislenemdaz
date created:
2014-07-11T09:21:31Z
date modified:
2024-09-07T15:15:35Z
main entity:
{"identifier":"Q18205913","url":"https://www.wikidata.org/entity/Q18205913"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/1/15/CERC-301.svg","width":512,"height":214}
fields total:
13
integrity:
16